Department of Oncological Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui Province, 233000, China.
Clin Exp Med. 2022 Aug;22(3):403-410. doi: 10.1007/s10238-021-00752-6. Epub 2021 Sep 17.
To study the role of HER2/cortactin co-overexpression in advanced gastric cancer (GC). This study retrospectively enrolled 246 patients with stage III GC from January 2015 to December 2016 at our hospital. We explored, using immunostaining techniques, the role of the expression of cortactin and HER2 in the progression of advanced GC. The patient data, including age, sex, cortactin and HER2 expression, pathological parameters and survival, were collected. Univariate and multivariate analyses were used to analyze the characteristics, survival, and prognostic factors of the patients. The results showed that the expression of cortactin was significantly associated with vascular-lymphatic invasion (P < 0.001), N stage (P = 0.001), and TNM stage (P = 0.046). HER2 overexpression correlated with tumor size (P = 0.002), neural invasion (P = 0.002), Lauren classification (P = 0.005) and N stage (P = 0.034). Through univariate analysis using the Kaplan-Meier method, vascular-lymphatic invasion (P = 0.015), neural invasion (P = 0.021), N stage (P < 0.003), and HER2/cortactin co-overexpression (P < 0.028) were shown to be significantly associated with overall survival. Multivariate analysis demonstrated that vascular lymphatic invasion (hazard ratio = 1.481, 95% CI, 1.064 to 2.061, P = 0.020), neural invasion (hazard ratio = 1.505, 95% CI, 1.084 to 2.089, P = 0.015), N stage (N2/N1: hazard ratio = 1.655, 95% CI, 1.048 to 2.641, P < 0.031, N3/N1: hazard ratio = 2.089, 95% CI, 1.325 to 3.295, P < 0.002), and HER2/cortactin co-overexpression (hazard ratio = 1.427, 95% CI, 1.007 to 2.024, P = 0.046) were independent prognostic factors for poor overall survival. The results suggested that HER2/cortactin co-overexpression is an important predictive biomarker for GC patients. GC patients with HER2/cortactin co-overexpression may receive dual-targeted therapy to improve survival prognosis in the future.
探讨 HER2/皮质肌动蛋白共过表达在晚期胃癌（GC）中的作用。本研究回顾性纳入 2015 年 1 月至 2016 年 12 月我院收治的 246 例 III 期 GC 患者。我们采用免疫组化技术探讨了皮质肌动蛋白和 HER2 的表达在晚期 GC 进展中的作用。收集了患者的年龄、性别、皮质肌动蛋白和 HER2 表达、病理参数和生存等数据。采用单因素和多因素分析对患者的特征、生存和预后因素进行分析。结果表明，皮质肌动蛋白的表达与血管淋巴管侵犯（P<0.001）、N 分期（P=0.001）和 TNM 分期（P=0.046）显著相关。HER2 过表达与肿瘤大小（P=0.002）、神经侵犯（P=0.002）、Lauren 分类（P=0.005）和 N 分期（P=0.034）相关。通过 Kaplan-Meier 方法的单因素分析，血管淋巴管侵犯（P=0.015）、神经侵犯（P=0.021）、N 分期（P<0.003）和 HER2/皮质肌动蛋白共过表达（P<0.028）与总生存显著相关。多因素分析表明，血管淋巴管侵犯（风险比=1.481，95%可信区间，1.064 至 2.061，P=0.020）、神经侵犯（风险比=1.505，95%可信区间，1.084 至 2.089，P=0.015）、N 分期（N2/N1：风险比=1.655，95%可信区间，1.048 至 2.641，P<0.031，N3/N1：风险比=2.089，95%可信区间，1.325 至 3.295，P<0.002）和 HER2/皮质肌动蛋白共过表达（风险比=1.427，95%可信区间，1.007 至 2.024，P=0.046）是总生存不良的独立预后因素。结果表明，HER2/皮质肌动蛋白共过表达是 GC 患者的一个重要预测生物标志物。HER2/皮质肌动蛋白共过表达的 GC 患者未来可能接受双重靶向治疗以改善生存预后。
